PRKDC and leukemia: Thus, it has been described that NU-7026, a DNA-PK inhibitor, potentiates the cytotoxicity of topoisomerase II poisons or doxorubicin used in the treatment of leukemia [70], synergizes with Irinotecan in colon cancer cells [71], and sensitizes cancer cells to ionizing radiation [72].